Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Psycho-cognitive predictors of burnout in healthcare professionals working in emergency departments.

Masiero M, Cutica I, Russo S, Mazzocco K, Pravettoni G.

J Clin Nurs. 2018 Jul;27(13-14):2691-2698. doi: 10.1111/jocn.14376. Epub 2018 Jun 1.

PMID:
29856096
2.

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study.

Berbegall AP, Bogen D, Pötschger U, Beiske K, Bown N, Combaret V, Defferrari R, Jeison M, Mazzocco K, Varesio L, Vicha A, Ash S, Castel V, Coze C, Ladenstein R, Owens C, Papadakis V, Ruud E, Amann G, Sementa AR, Navarro S, Ambros PF, Noguera R, Ambros IM.

Br J Cancer. 2018 May 14. doi: 10.1038/s41416-018-0098-6. [Epub ahead of print]

PMID:
29755120
3.

E-cigarettes May Support Smokers With High Smoking-Related Risk Awareness to Stop Smoking in the Short Run: Preliminary Results by Randomized Controlled Trial.

Masiero M, Lucchiari C, Mazzocco K, Veronesi G, Maisonneuve P, Jemos C, Salè EO, Spina S, Bertolotti R, Pravettoni G.

Nicotine Tob Res. 2018 Apr 11. doi: 10.1093/ntr/nty047. [Epub ahead of print]

PMID:
29660034
4.

Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.

Depuydt P, Boeva V, Hocking TD, Cannoodt R, Ambros IM, Ambros PF, Asgharzadeh S, Attiyeh EF, Combaret V, Defferrari R, Fischer M, Hero B, Hogarty MD, Irwin MS, Koster J, Kreissman S, Ladenstein R, Lapouble E, Laureys G, London WB, Mazzocco K, Nakagawara A, Noguera R, Ohira M, Park JR, Pötschger U, Theissen J, Tonini GP, Valteau-Couanet D, Varesio L, Versteeg R, Speleman F, Maris JM, Schleiermacher G, De Preter K.

J Natl Cancer Inst. 2018 Mar 5. doi: 10.1093/jnci/djy022. [Epub ahead of print]

PMID:
29514301
5.

Decisions and the involvement of cancer patient survivors: a moral imperative.

Pravettoni G, Cutica I, Righetti S, Mazzocco K.

J Healthc Leadersh. 2016 Dec 7;8:121-125. doi: 10.2147/JHL.S115434. eCollection 2016.

6.

A Qualitative Investigation on Patient Empowerment in Prostate Cancer.

Renzi C, Fioretti C, Oliveri S, Mazzocco K, Zerini D, Alessandro O, Rojas DP, Jereczek-Fossa BA, Pravettoni G.

Front Psychol. 2017 Jul 26;8:1215. doi: 10.3389/fpsyg.2017.01215. eCollection 2017.

7.

Professor Umberto Veronesi: a physician, a researcher, a brilliant man.

Mazzocco K, Marzorati C, Pravettoni G.

Ecancermedicalscience. 2017 Jun 8;11:742. doi: 10.3332/ecancer.2017.742. eCollection 2017.

8.

Constitutional 3p26.3 terminal microdeletion in an adolescent with neuroblastoma.

Pezzolo A, Sementa AR, Lerone M, Morini M, Ognibene M, Defferrari R, Mazzocco K, Conte M, Gigliotti AR, Garaventa A, Pistoia V, Varesio L.

Cancer Biol Ther. 2017 May 4;18(5):285-289. doi: 10.1080/15384047.2017.1312231. Epub 2017 Apr 12.

9.

How many research nurses for how many clinical trials in an oncology setting? Definition of the Nursing Time Required by Clinical Trial-Assessment Tool (NTRCT-AT).

Milani A, Mazzocco K, Stucchi S, Magon G, Pravettoni G, Passoni C, Ciccarelli C, Tonali A, Profeta T, Saiani L.

Int J Nurs Pract. 2017 Feb;23(1). doi: 10.1111/ijn.12497. Epub 2016 Dec 7.

PMID:
27925377
10.

A web-based interactive tool to improve breast cancer patient centredness.

Gorini A, Mazzocco K, Kondylakis H, McVie G, Pravettoni G.

Ecancermedicalscience. 2016 Jul 26;10:659. doi: 10.3332/ecancer.2016.659. eCollection 2016.

11.

Promoting weight loss through diet and exercise in overweight or obese breast cancer survivors (InForma): study protocol for a randomized controlled trial.

Gnagnarella P, Dragà D, Baggi F, Simoncini MC, Sabbatini A, Mazzocco K, Bassi FD, Pravettoni G, Maisonneuve P.

Trials. 2016 Jul 28;17:363. doi: 10.1186/s13063-016-1487-x.

12.

Research studies on patients' illness experience using the Narrative Medicine approach: a systematic review.

Fioretti C, Mazzocco K, Riva S, Oliveri S, Masiero M, Pravettoni G.

BMJ Open. 2016 Jul 14;6(7):e011220. doi: 10.1136/bmjopen-2016-011220. Review.

13.

Psycho-emotional tools for better treatment adherence and therapeutic outcomes for cancer patients.

Kazantzaki E, Kondylakis H, Koumakis L, Marias K, Tsiknakis M, Fioretti C, Gorini A, Mazzocco K, Renzi C, Pravettoni G.

Stud Health Technol Inform. 2016;224:129-34.

14.

Piloting the European Unified Patient Identity Management (EUPID) Concept to Facilitate Secondary Use of Neuroblastoma Data from Clinical Trials and Biobanking.

Ebner H, Hayn D, Falgenhauer M, Nitzlnader M, Schleiermacher G, Haupt R, Erminio G, Defferrari R, Mazzocco K, Kohler J, Tonini GP, Ladenstein R, Schreier G.

Stud Health Technol Inform. 2016;223:31-8.

PMID:
27139382
15.

Incidence and Determinants of Port Occlusions in Cancer Outpatients: A Prospective Cohort Study.

Milani A, Mazzocco K, Gandini S, Pravettoni G, Libutti L, Zencovich C, Sbriglia A, Pari C, Magon G, Saiani L.

Cancer Nurs. 2017 Mar/Apr;40(2):102-107. doi: 10.1097/NCC.0000000000000357.

PMID:
26925994
16.

Understanding cognitive processes behind acceptance or refusal of phase I trials.

Pravettoni G, Mazzocco K, Gorini A, Curigliano G.

Crit Rev Oncol Hematol. 2016 Apr;100:69-73. doi: 10.1016/j.critrevonc.2016.01.023. Epub 2016 Jan 23. Review.

PMID:
26852078
17.

Rationale and protocol of CML study: cognitive and emotional impact of discontinuation of therapy in patients with chronic myeloid leukemia.

Riva S, Mazzocco K, Pravettoni G.

Tumori. 2016 Mar-Apr;102(2):217-21. doi: 10.5301/tj.5000451. Epub 2015 Dec 11.

PMID:
26689667
18.

Eliminating "ductal carcinoma in situ" and "lobular carcinoma in situ" (DCIS and LCIS) terminology in clinical breast practice: The cognitive psychology point of view.

Pravettoni G, Yoder WR, Riva S, Mazzocco K, Arnaboldi P, Galimberti V.

Breast. 2016 Feb;25:82-5. doi: 10.1016/j.breast.2015.10.011. Epub 2015 Nov 21.

PMID:
26614547
19.

Decision-Making Process Related to Participation in Phase I Clinical Trials: A Nonsystematic Review of the Existing Evidence.

Gorini A, Mazzocco K, Pravettoni G.

Public Health Genomics. 2015;18(6):359-65. doi: 10.1159/000441559. Epub 2015 Nov 4. Review.

PMID:
26529420
20.

The Paradox of Pelvic Exenteration: The Interaction of Clinical and Psychological Variables.

Arnaboldi P, Santoro L, Mazzocco K, Oliveri S, Maggioni A, Pravettoni G.

Int J Gynecol Cancer. 2015 Oct;25(8):1534-40. doi: 10.1097/IGC.0000000000000523.

PMID:
26244759
21.

Development and psychometric testing of a breast cancer patient-profiling questionnaire.

Gorini A, Mazzocco K, Gandini S, Munzone E, McVie G, Pravettoni G.

Breast Cancer (Dove Med Press). 2015 Jun 1;7:133-46. doi: 10.2147/BCTT.S80014. eCollection 2015.

22.

Genetic abnormalities in adolescents and young adults with neuroblastoma: A report from the Italian Neuroblastoma group.

Mazzocco K, Defferrari R, Sementa AR, Garaventa A, Longo L, De Mariano M, Esposito MR, Negri F, Ircolò D, Viscardi E, Luksch R, D'Angelo P, Prete A, Castellano A, Massirio P, Erminio G, Gigliotti AR, Tonini GP, Conte M.

Pediatr Blood Cancer. 2015 Oct;62(10):1725-32. doi: 10.1002/pbc.25552. Epub 2015 Apr 29.

PMID:
25925003
23.

Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.

Defferrari R, Mazzocco K, Ambros IM, Ambros PF, Bedwell C, Beiske K, Bénard J, Berbegall AP, Bown N, Combaret V, Couturier J, Erminio G, Gambini C, Garaventa A, Gross N, Haupt R, Kohler J, Jeison M, Lunec J, Marques B, Martinsson T, Noguera R, Parodi S, Schleiermacher G, Tweddle DA, Valent A, Van Roy N, Vicha A, Villamon E, Tonini GP.

Br J Cancer. 2015 Jan 20;112(2):290-5. doi: 10.1038/bjc.2014.557. Epub 2014 Nov 4.

24.

Neuroblastoma in the adult: the Italian experience with 21 patients.

Sorrentino S, Gigliotti AR, Sementa AR, Morsellino V, Conte M, Erminio G, Buffa P, Granata C, Mazzocco K, Garaventa A, De Bernardi B.

J Pediatr Hematol Oncol. 2014 Nov;36(8):e499-505. doi: 10.1097/MPH.0000000000000144.

PMID:
24633299
25.

Development of interactive empowerment services in support of personalised medicine.

Kondylakis H, Kazantzaki E, Koumakis L, Genitsaridi I, Marias K, Gorini A, Mazzocco K, Pravettoni G, Burke D, McVie G, Tsiknakis M.

Ecancermedicalscience. 2014 Feb 11;8:400. doi: 10.3332/ecancer.2014.400. eCollection 2014. Review.

26.

Constitutional 11q14-q22 chromosome deletion syndrome in a child with neuroblastoma MYCN single copy.

Passariello A, De Brasi D, Defferrari R, Genesio R, Tufano M, Mazzocco K, Capasso M, Migliorati R, Martinsson T, Siani P, Nitsch L, Tonini GP.

Eur J Med Genet. 2013 Nov;56(11):626-34. doi: 10.1016/j.ejmg.2013.08.005. Epub 2013 Sep 13.

PMID:
24035971
27.

Bone marrow-infiltrating human neuroblastoma cells express high levels of calprotectin and HLA-G proteins.

Morandi F, Scaruffi P, Gallo F, Stigliani S, Moretti S, Bonassi S, Gambini C, Mazzocco K, Fardin P, Haupt R, Arcamone G; Italian Cooperative Group for Neuroblastoma, Pistoia V, Tonini GP, Corrias MV.

PLoS One. 2012;7(1):e29922. doi: 10.1371/journal.pone.0029922. Epub 2012 Jan 9.

28.

Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).

Schleiermacher G, Michon J, Ribeiro A, Pierron G, Mosseri V, Rubie H, Munzer C, Bénard J, Auger N, Combaret V, Janoueix-Lerosey I, Pearson A, Tweddle DA, Bown N, Gerrard M, Wheeler K, Noguera R, Villamon E, Cañete A, Castel V, Marques B, de Lacerda A, Tonini GP, Mazzocco K, Defferrari R, de Bernardi B, di Cataldo A, van Roy N, Brichard B, Ladenstein R, Ambros I, Ambros P, Beiske K, Delattre O, Couturier J.

Br J Cancer. 2011 Dec 6;105(12):1940-8. doi: 10.1038/bjc.2011.472. Epub 2011 Nov 10.

29.

Pecunia olet: the role of incidental disgust in the ultimatum game.

Bonini N, Hadjichristidis C, Mazzocco K, Demattè ML, Zampini M, Sbarbati A, Magon S.

Emotion. 2011 Aug;11(4):965-9. doi: 10.1037/a0022820.

PMID:
21534658
30.

A multilocus technique for risk evaluation of patients with neuroblastoma.

Ambros IM, Brunner B, Aigner G, Bedwell C, Beiske K, Bénard J, Bown N, Combaret V, Couturier J, Defferrari R, Gross N, Jeison M, Lunec J, Marques B, Martinsson T, Mazzocco K, Noguera R, Schleiermacher G, Speleman F, Stallings R, Tonini GP, Tweddle DA, Valent A, Vicha A, Roy NV, Villamon E, Ziegler A, Preuner S, Drobics M, Ladenstein R, Amann G, Schuit RJ, Pötschger U, Ambros PF.

Clin Cancer Res. 2011 Feb 15;17(4):792-804. doi: 10.1158/1078-0432.CCR-10-0830.

31.

Simultaneous tumors: acute myeloid leukemia infiltrating mediastinal ganglioneuroblastoma.

Di Cataldo A, Mazzocco K, Magro G, Mirabile E, Lo Nigro L, Defferrari R, Tonini GP.

Pediatr Blood Cancer. 2011 Feb;56(2):298-300. doi: 10.1002/pbc.22807.

PMID:
20973101
32.

The effect of outcome information on health professionals' spontaneous learning.

Mazzocco K, Cherubini P.

Med Educ. 2010 Oct;44(10):962-8. doi: 10.1111/j.1365-2923.2010.03744.x.

PMID:
20880365
33.

MDM2 SNP309 genotype is associated with ferritin and LDH serum levels in children with stage 4 neuroblastoma.

Parodi S, Perfumo C, Garaventa A, Inga A, Mazzocco K, Defferrari R, Tonini GP, Fronza G, Haupt R.

Pediatr Blood Cancer. 2010 Aug;55(2):267-72. doi: 10.1002/pbc.22477.

PMID:
20232446
34.

The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis.

Paradiso A, Mangia A, Orlando C, Verderio P, Belfiglio M, Marchetti A, Bertario L, Chiappetta G, Gion M, Tonini GP, Podo F, Vocaturo A, Silvestrini R, Romani M, Belloni E, Cavallo D, Ulivi P, Tommasi S, Steffan A, Russo A, Alessio M, Calistri D, Zancan M, Parrela P, Broggini M, Giuseppe A, Buttitta F, Finocchiaro G, Mazzocco K, Veronesi G, Landuzzi L, Benevolo M, Mariani L, De Marco F, Venuti A, Giannelli G, Quaranta M, Trojano V.

Int J Biol Markers. 2009 Jul-Sep;24(3):119-29.

PMID:
19787622
35.

Outcome prediction and risk assessment by quantitative pyrosequencing methylation analysis of the SFN gene in advanced stage, high-risk, neuroblastic tumor patients.

Banelli B, Bonassi S, Casciano I, Mazzocco K, Di Vinci A, Scaruffi P, Brigati C, Allemanni G, Borzì L, Tonini GP, Romani M.

Int J Cancer. 2010 Feb 1;126(3):656-68. doi: 10.1002/ijc.24768.

36.

MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma.

Perfumo C, Parodi S, Mazzocco K, Defferrari R, Inga A, Scarrà GB, Ghiorzo P, Haupt R, Tonini GP, Fronza G.

Pediatr Blood Cancer. 2009 Oct;53(4):576-83. doi: 10.1002/pbc.22132.

PMID:
19526525
37.

Impact of MDM2 SNP309 genotype on progression and survival of stage 4 neuroblastoma.

Perfumo C, Parodi S, Mazzocco K, Defferrari R, Inga A, Haupt R, Fronza G, Tonini GP.

Eur J Cancer. 2008 Nov;44(17):2634-9. doi: 10.1016/j.ejca.2008.08.018. Epub 2008 Oct 1.

PMID:
18835771
38.

Surgical team behaviors and patient outcomes.

Mazzocco K, Petitti DB, Fong KT, Bonacum D, Brookey J, Graham S, Lasky RE, Sexton JB, Thomas EJ.

Am J Surg. 2009 May;197(5):678-85. doi: 10.1016/j.amjsurg.2008.03.002. Epub 2008 Sep 11.

PMID:
18789425
39.

Risk factors for non-adherence to medication in inflammatory bowel disease patients.

D'Incà R, Bertomoro P, Mazzocco K, Vettorato MG, Rumiati R, Sturniolo GC.

Aliment Pharmacol Ther. 2008 Jan 15;27(2):166-72. Epub 2007 Oct 20.

40.

Identification and characterization of DNA imbalances in neuroblastoma by high-resolution oligonucleotide array comparative genomic hybridization.

Scaruffi P, Coco S, Cifuentes F, Albino D, Nair M, Defferrari R, Mazzocco K, Tonini GP.

Cancer Genet Cytogenet. 2007 Aug;177(1):20-9.

PMID:
17693187
41.

Concomitant DDX1 and MYCN gain in neuroblastoma.

Defferrari R, Tonini GP, Conte M, Papio F, Sementa AR, Valent A, Schena F, Perri P, Mazzocco K.

Cancer Lett. 2007 Oct 18;256(1):56-63. Epub 2007 Jul 3.

PMID:
17611020
42.

Numeracy and decision making.

Peters E, Västfjäll D, Slovic P, Mertz CK, Mazzocco K, Dickert S.

Psychol Sci. 2006 May;17(5):407-13.

PMID:
16683928
43.

Neuroblastoma in adolescents: the Italian experience.

Conte M, Parodi S, De Bernardi B, Milanaccio C, Mazzocco K, Angelini P, Viscardi E, Di Cataldo A, Luksch R, Haupt R.

Cancer. 2006 Mar 15;106(6):1409-17.

44.

Genome analysis and gene expression profiling of neuroblastoma and ganglioneuroblastoma reveal differences between neuroblastic and Schwannian stromal cells.

Coco S, Defferrari R, Scaruffi P, Cavazzana A, Di Cristofano C, Longo L, Mazzocco K, Perri P, Gambini C, Moretti S, Bonassi S, Tonini GP.

J Pathol. 2005 Nov;207(3):346-57.

PMID:
16178058
45.

[The framing effect: medical implications].

Mazzocco K, Cherubini P, Rumiati R.

Ann Ital Med Int. 2005 Jan-Mar;20(1):1-9. Review. Italian.

PMID:
15859389
46.

Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization.

Scaruffi P, Parodi S, Mazzocco K, Defferrari R, Fontana V, Bonassi S, Tonini GP.

Mol Diagn. 2004;8(2):93-100.

PMID:
15527323
47.

Biological and clinical role of p73 in neuroblastoma.

Romani M, Tonini GP, Banelli B, Allemanni G, Mazzocco K, Scaruffi P, Boni L, Ponzoni M, Pagnan G, Raffaghello L, Ferrini S, Croce M, Casciano I.

Cancer Lett. 2003 Jul 18;197(1-2):111-7. Review.

PMID:
12880969
48.

Quality assessment of genetic markers used for therapy stratification.

Ambros IM, Benard J, Boavida M, Bown N, Caron H, Combaret V, Couturier J, Darnfors C, Delattre O, Freeman-Edward J, Gambini C, Gross N, Hattinger CM, Luegmayr A, Lunec J, Martinsson T, Mazzocco K, Navarro S, Noguera R, O'Neill S, Potschger U, Rumpler S, Speleman F, Tonini GP, Valent A, Van Roy N, Amann G, De Bernardi B, Kogner P, Ladenstein R, Michon J, Pearson AD, Ambros PF.

J Clin Oncol. 2003 Jun 1;21(11):2077-84.

PMID:
12775732
49.

Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases.

Gambini C, Conte M, Bernini G, Angelini P, Pession A, Paolucci P, Donfrancesco A, Veneselli E, Mazzocco K, Tonini GP, Raffaghello L, Dominici C, Morando A, Negri F, Favre A, De Bernardi B, Pistoia V.

Virchows Arch. 2003 Jun;442(6):555-62. Epub 2003 Apr 23.

PMID:
12709798
50.

Homozygous inactivation of NF1 gene in a patient with familial NF1 and disseminated neuroblastoma.

Origone P, Defferrari R, Mazzocco K, Lo Cunsolo C, De Bernardi B, Tonini GP.

Am J Med Genet A. 2003 May 1;118A(4):309-13.

PMID:
12687660

Supplemental Content

Loading ...
Support Center